Treatment choices for older women with primary operable breast cancer and cognitive impairment: Results from a prospective, multicentre cohort study. by Martin, Charlene et al.
Treatment choices for older women with primary operable 
breast cancer and cognitive impairment: Results from a 
prospective, multicentre cohort study.
MARTIN, Charlene, SHRESTHA, Anne, MORGAN, Jenna, BRADBURN, 
Michael, HERBERT, Esther, BURTON, Maria <http://orcid.org/0000-0002-
5411-8181>, TODD, Annaliza, WALTERS, Stephen, WARD, Sue, HOLMES, 
Geoffrey, REED, Malcolm, COLLINS, Karen <http://orcid.org/0000-0002-4317-
142X>, ROBINSON, Thompson G, RING, Alistair, CHEUNG, Kwok-Leung, 
AUDISIO, Riccardo, GATH, Jacqui, REVELL, Deirdre, GREEN, Tracy, 
LIFFORD, Kate, EDWARDS, Adrian, CHATER, Tim, PEMBERTON, Kirsty and 
WYLD, Lynda
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/27906/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
MARTIN, Charlene, SHRESTHA, Anne, MORGAN, Jenna, BRADBURN, Michael, 
HERBERT, Esther, BURTON, Maria, TODD, Annaliza, WALTERS, Stephen, WARD, 
Sue, HOLMES, Geoffrey, REED, Malcolm, COLLINS, Karen, ROBINSON, 
Thompson G, RING, Alistair, CHEUNG, Kwok-Leung, AUDISIO, Riccardo, GATH, 
Jacqui, REVELL, Deirdre, GREEN, Tracy, LIFFORD, Kate, EDWARDS, Adrian, 
CHATER, Tim, PEMBERTON, Kirsty and WYLD, Lynda (2020). Treatment choices 
for older women with primary operable breast cancer and cognitive impairment: 
Results from a prospective, multicentre cohort study. Journal of Geriatric Oncology. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Journal of Geriatric Oncology xxx (xxxx) xxx
JGO-01080; No. of pages: 9; 4C:
Contents lists available at ScienceDirect
Journal of Geriatric OncologyTreatment choices for older women with primary operable breast
cancer and cognitive impairment: Results from a prospective,
multicentre cohort studyCharlene Martin a, Anne Shrestha a, Jenna Morgan a, Michael Bradburn b, Esther Herbert b, Maria Burton c,
Annaliza Todd a, Stephen Walters c, Sue Ward d, Geoffrey Holmes d, Malcolm Reed e, Karen Collins c,
Thompson G. Robinson f, Alistair Ring j, Kwok-Leung Cheung g, Riccardo Audisio h, Jacqui Gath i, Deirdre Revell i,
Tracy Green i, Kate Lifford k, Adrian Edwards k, Tim Chater b, Kirsty Pemberton b, Lynda Wyld a,⁎
a Department of Oncology and Metabolism, University of Sheffield, The Medical School, Beech Hill Road, Sheffield S10 2RX, UK
b Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
c Centre for Health and Social Care Research, Sheffield Hallam University, Collegiate Crescent, Sheffield, UK
d Department of Health Economics and Decision Science, School for Health and Related Research, University of Sheffield, Sheffield, UK
e Brighton and Sussex Medical School, Falmer, Brighton, UK
f Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, The Glenfield Hospital, Leicester LE3 9QP, UK
g School of Medicine, University of Nottingham, Royal Derby Hospital Centre, Uttoxeter Road, Derby DE22 3DT, UK
h Department of Surgery, Institute of Clinical Sciences, Blå Stråket 5, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
i Yorkshire and Humber Consumer Research Panel, UK
j Breast Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK
k Division of Population Medicine, School of Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff CF14 4YS, UK⁎ Corresponding author.
E-mail address: l.wyld@sheffield.ac.uk (L. Wyld).
https://doi.org/10.1016/j.jgo.2020.12.006
1879-4068/© 2020 The Author(s). Published by Elsevier L
Please cite this article as: C. Martin, A. Shres
cognitive impairment: Resu..., J Geriatr Oncoa b s t r a c ta r t i c l e i n f oArticle history:
Received 3 July 2020
Received in revised form 16 November 2020







Breast cancerObjectives: The presence of dementia co-existingwith a diagnosis of breast cancermay rendermanagementmore
challenging and have a substantial impact on oncological outcomes. The aim of this study was to examine the
treatment and outcomes of older women with co-existing cognitive impairment and primary breast cancer.
Materials andmethods: A prospective, multicentre UK cohort study ofwomen aged 70 years or overwith primary
operable breast cancer. Patients with and without cognitive impairment were compared to assess differences in
treatment and survival outcomes.
Results: In total, 3416womenwere recruited between 2013 and 2018. Of these, 478 (14%) had a diagnosis of de-
mentia or cognitive impairment, subcategorised as mild, moderate and severely impaired. Up to 85% of women
with normal cognition underwent surgery compared to 74%, 61% and 40% with mild, moderate, and severe im-
pairment (p=0.001). Amongwomen at higher risk of recurrence, the uptake of chemotherapy was 25% for cog-
nitively normal women compared to 20%, 22% and 12% for mild, moderate and severe impairment groups (p=
0.222). Radiotherapy usewas similar in the subgroups. Although patients with cognitive impairment had shorter
overall survival (HR: 2.10, 95% CI: 1.77–2.50, p < 0.001), there were no statistically significant differences in
breast cancer specific or progression-free survival.
Conclusion: Cognitive impairment appears to play a significant part in deciding how to treat older women with
breast cancer. Standard treatment may be over-treatment for some women with severe dementia and careful
consideration must be given to a more tailored approach in these women.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Many diseases and co-morbidities are linked to ageing; the majority
of cancers are more prevalent in older age groups and often present in
patients with age-related co-morbidities, including dementia. Withtd. This is an open access article und
tha, J. Morgan, et al., Treatme
l, https://doi.org/10.1016/j.jgincreasing age, the possibility of having a co-existing cancer and a diag-
nosis of dementia increases [1] and is associated with decreased cancer
specific and overall survival [2,3].
It is estimated that 7–10% of breast cancer patients have a co-
existent diagnosis of cognitive impairment (CI) or dementia [4]. Com-
pared to non-cognitively impaired patients, this group has a six-fold
higher risk of all-cause mortality within two years of diagnosis, which
emphasises the importance of minimising treatment morbidity in thiser the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nt choices for older women with primary operable breast cancer and
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[6],which contributes to inferior breast cancer specific survival for these
women [4,7]. Overall survival is also reduced in patients with dementia
and cancer, as dementia increases the risk of all-cause mortality [8], in
particular pneumonia [9]. Our previous analysis of UK registry data
showed that patients with breast cancer and dementia have inferior
overall and breast cancer specific survival if surgery is omitted [10]. De-
mentia was also an independent risk factor for non-guideline concor-
dant care [4,11].
People living with dementia may present complex challenges from
legal, ethical, and practical perspectives, particularly in cases where
the patient does not have capacity to give informed consent to treat-
ment and has not put in place an advance care plan. Dementia itself is
a complex disease with multiple aetiologies and symptoms including
memory loss, lack of cognitive capacity, confusion, and anxiety. The im-
pact of cancer treatmentswill vary according to the severity of dementia
and ability to monitor side effects. Surgery under general anaesthetic in
the over 70s may cause prolonged post-operative cognitive dysfunction
[12], acute post-operative delirium [13], and long-term cognitive de-
cline, especially followingmajor surgical resections, further compromis-
ing cognitive function [14]. The precise aetiology of this is not clear [15].
Cognitive impairment may also complicate the delivery of adjuvant
treatments, including chemotherapy. For example, it is vital that pa-
tients receiving chemotherapy proactively report side-effects, including
fever, which may signal life-threatening sepsis. Furthermore, patients
undergoing chemotherapy may experience a degree of cognitive dys-
function, such as chemo-brain, which might exacerbate existing cogni-
tion problems in a person living with dementia [16,17].
In some cases, reduced life expectancy may reduce the risk of breast
cancer mortality, especially with indolent cancers, and some low grade,
oestrogen receptor positive (ER+) breast cancers. Primary endocrine
therapy (PET), where surgery is omitted inwomenwith ER+breast can-
cer,may be selected in these situations, trading reduced therapeutic ben-
efit (reduced breast cancer specific survival and a higher rate of local
disease progression) against reduced surgical morbidity [18]. Primary
endocrine therapy is not without adverse effects. These may include
hot flushes, bone density loss and joint pain due to use of aromatase in-
hibitors, although the majority of women who have surgery will also be
advised to take adjuvant aromatase inhibitors therapy for 5 years, so
these side effects will affect both groups equally [19]. Some women
with very low risk ER+ breast cancer may safely omit adjuvant endo-
crine therapy after surgery, especially in countries like the Netherlands
where guidelines do not advise endocrine therapy for low risk ER+
breast cancers. The main disadvantage of PET is the risk of development
of endocrine resistance after amedian of ~3 years whichmay necessitate
a change ofmanagement and an increased risk of failure of local and sys-
temic disease control.
The decision-making process to select treatments for older patients
is complex and wide variation exists in their use [20,21]. The treatment
decision-making process for patients with dementia is therefore chal-
lenging and should include consideration of the cancer prognosis, the
physical health of the patient, the degree of dementia or impairment,
and the wishes of the patient and their caregivers. The aims of this
study were to examine a large prospective UK cohort of older women
with primary breast cancer, with or without co-existing CI or dementia,
and evaluate their treatment patterns and survival outcomes.2. Materials and Methods
2.1. Study Design
Ethics approval was granted by London South East Research Ethics
Committee in November 2012 (12/LO/1808, IRAS ID: 115550). All pa-
tients (or their caregivers) gave written informed consent. The recruit-
ment of participants with a formal diagnosis of dementiawas compliant2
with Section 33 of theMental Capacity Act (UK legislation to protect the
rights of people with cognitive impairment) [22,23].
Bridging the Age Gap in Breast Cancer was a prospective UK
multicentre cohort study,which collected data onpatient and cancer char-
acteristics, treatment allocation, and survival outcomes in older women
(>70) with primary operable breast cancer [24–26].
To identify individuals with CI, participants who were assented to
the study by a consultee were categorised as having severe impairment,
as proxy consent was an indicator for the patient being unable to give
informed consent to participate in the study. Where patients gave in-
formed consent to participate, cognition statuswas ascertained through
completion of the Charlson Index [27] form or the MMSE. The MMSE
scored participants as having mild, moderate, or severe impairment ac-
cording to standard scoring protocols (normal [27–30], mild CI [21–26],
moderate CI [11–20], and severe CI (0−10)) [28]. The MMSE score al-
ways took precedence over Charlson Index categorisation if available,
with participants re-categorised according toMMSE score.Where avail-
able, a review of current medications was also performed. Participants
who were able to give informed consent to join the study and had no
other indication of impairmentwere assumed to have normal cognition.
2.2. Study Data Collection
2.2.1. Baseline
Patient demographics and co-morbidity data were collected using a
Modified Charlson Index score; for the purposes of this analyses, age
and presence of dementia were omitted from the standard calculation.
Functional status was determined by the validated Activities of Daily Liv-
ing (ADL) score [29], Instrumental Activities of Daily Living (IADL) [30]
and the Eastern Cooperative Oncology Group performance status
(ECOG-PS) [31] scores. Nutritional statuswas assessedusing theAbridged
Patient Generated Subjective Global Assessment (aPG-SGA) [32–34].
Scoring of each tool followed standard published criteria. Primary breast
tumour characteristics collected included grade, biological subtype and
tumour stage (clinical, imaging and pathological stage used the TNM sys-
tem, Version 8 [35]). Pathological axillary stage was not collected for pa-
tients who did not have surgery, but clinical assessment and pre-
operative ultrasound and biopsy of nodal disease were recorded.
2.2.2. Follow-up
All patients were directly followed up at 6 weeks, and at 6, 12, 18,
and 24 months to collect data on the treatment they received, adverse
events, recurrence, and survival. Cause of death was assessed by certifi-
cation and classed as either breast cancer-specific or other cause. Recur-
rence and mortality were obtained directly from participating breast
cancer units for up to 24 months and from the UK cancer registry (fol-
lowing specific patient or caregiver consent) for up to a median
follow-up of 52 months.
2.2.3. Recruitment and Eligibility
Recruitment took place at 56 breast cancer units in England and
Wales between February 2013 and June 2018. Participants were re-
cruited after a new diagnosis of primary operable breast cancer. Eligibil-
ity criteria: women aged 70 or over, primary operable breast cancer
(TNM: T1-3 and some T4b, N0-1,M0). Exclusion criteria:metastatic dis-
ease, previous invasive breast cancer within five years. There were no
limits for language or cognitive function.
2.2.4. Data Analysis
Statistical analyses were performed in IBM SPSS (Version 26.0) and
Stata (Version 16.1). Each patient or tumour characteristic was
summarised in relation to cognitive category. Discrete characteristics
were summarised by numbers and percentages, with statistical signifi-
cance assessed by Chi-squared test. Continuous characteristics were
summarised as the median and range, and statistical significance
assessed by a non-parametric Kruskal Wallis test.
C. Martin, A. Shrestha, J. Morgan et al. Journal of Geriatric Oncology xxx (xxxx) xxxOverall survival and breast cancer specific survival were both com-
pared between patients with CI (of any severity) and without impair-
ment by propensity score matching. Two matching approaches were
used. In the first analysis, patients with CI were matched with up to
three non-impaired patients that had the same category of Nottingham
Prognostic Index (NPI; risk categories ≤3.4, >3.4 to ≤5.4, >5.4),
oestrogen receptivity (ER) and treatment (surgery and ER+, surgery
and ER-, PET and ER+), and age to within a calliper width of one year
(approximately 1/6th of a standard deviation) [36]. The second
approach matched on NPI category, ER category, and treatment and
also a more detailed propensity score including functionality (ADL,
IADL, and ECOG), nutrition (aPG-SGA) and co-morbidity (CCI scoreFig. 1. Study recruitment summ
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excluding dementia and age) to a calliper of 0.015 propensity score
units (approximately 0.2 standard deviations) with up to two matches
allowed. The comparisons were quantified by Kaplan-Meier curves
and Cox regression, presented for unadjusted and the matched analy-
ses; matching was accounted for by use of shared frailty terms [37].
3. Results
3.1. Patient Characteristics
A total of 3416 women were included in the analysis. Of these, 2938
(86%) were considered to have normal cognition and 478 (14%) hadary (patient flow diagram).
Table 1
Baseline demographics and characteristics of study participants by cognitive impairment level.
Cognition category
Normal function (N = 2938) Mild impairment (N = 336) Moderate impairment (N = 59) Severe impairment (N = 83) P value
Age
Median (range) 76 (69–102) 79 (70–96) 80 (70–99) 83 (70–97) <0.001
ADL Score⁎
Completed 2607 (88.7%) 321 (95.5%) 57 (96.6%) 33 (39.8%)
Median Score (range) 100 (5–100) 100 (30−100) 100 (30–100) 70 (20−100) <0.001
Percentage (%) of women scoringa
100 1982 (76.0%) 194 (60.4%) 29 (50.9%) 4 (12.1%)
95 314 (12.0%) 40 (12.5%) 7 (12.3%) 2 (6.1%)
≤90 311 (11.9% 87 (27.1%) 21 (36.8%) 27 (81.8%)
IADL Scoreb
Median (range) 8 (0–8) 8 (0–8) 7 (0–8) 2 (0–8) <0.001
CCI Scorec
Median (range) 1 (0−13) 1 (0–7) 1 (0–8) 2 (0–7) <0.001
a ADL scored according to Lawton and Brody (1969).
b IADL scored according to Lawton and Brody (1969).
c Age and presence of dementia was omitted from the CCI calculation.
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tion or a previous diagnosis of dementia (summarised in Fig. 1). Theme-
dian age of womenwith normal cognition was 76 years (range 69–102;
five women attended shortly before their 70th birthday and were
retained in the study), while women with mild, moderate and severe
CI had a median age of 79, 80 and 83, respectively. ADL, IADL and CCI
scores are summarised in Table 1.3.2. Tumour Characteristics
Tumour characteristics were similar between groups, with no statis-
tically significant difference found in terms of nodal status, grade, ERTable 2
Tumour characteristics of study participants by cognitive impairment level.
Cognition category
Tumour characteristics Normal function Mild impairment
Unilateral 2871 (97.7%) 326 (97.0%)
Bilateral 67 (2.3%) 10 (3.0%)
Size
T1 1745 (59.4%) 205 (61.0%)
T2 1110 (37.8%) 122 (36.3%)
T3 71 (2.4%) 8 (2.4%)
Unknown 12 (0.4%) 1 (0.3%)
Number of positive nodes
None 2468 (84.0%) 284 (84.5%)
1–3 380 (12.9%) 44 (13.1%)
4 + 23 (0.8%) 1 (0.3%)
Unknown 67 (2.3%) 7 (2.1%)
Provisional grade
1 455 (15.5%) 48 (14.3%)
2 1760 (59.9%) 212 (63.1%)
3 587 (20.0%) 62 (18.5%)
Unknown 136 (4.6%) 14 (4.2%)
Nottingham Prognostic Index (NPI)
≤3.4 1290 (43.9%) 139 (41.4%)
>3.4 to ≤5.4 1297 (44.1%) 159 (47.3%)
>5.4 121 (4.1%) 11 (3.3%)
Unknown 230 (7.8%) 27 (8.0%)
ER
Negative 343 (11.7%) 40 (11.9%)
Positive 2561 (87.2%) 292 (86.9%)
Unknown 34 (1.2%) 4 (1.2%)
HER2
Negative 1992 (67.8%) 207 (61.6%)
Inconclusive 83 (2.8%) 12 (3.6%)
Positive 283 (9.6%) 37 (11.0%)
Unknown 580 (19.7%) 80 (23.8%)
⁎ p-value excludes patients with missing or unknown data.
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andHER2 status. Therewas difference in the size of tumour at presenta-
tion;womenwithmoderate or severe CIweremore likely to have larger
tumours than women with normal cognition (Chi-squared, p < 0.001)
Table 2.3.3. Treatment Selection
Primary treatment data were available for 3315 patients, of whom
2811 (82.3%) underwent surgery (+/− adjuvant treatment) and 504
(14.8%) were treated with PET. Only 365/2938 (12.4%) of women with
normal cognition were treated with PET compared to 75/336 (22.3%)
of women with mild, 21/59 (35.6%) moderate and 43/83 (51.8%) withModerate impairment Severe impairment Total P value ⁎
59 (100%) 79 (95.2%) 3335 (97.6%) 0.24
0 (0%) 4 (4.8%) 81 (2.4%)
29 (49.2%) 34 (41.0%) 2013 (58.9%) <0.001
24 (40.7%) 48 (57.8%) 1304 (38.2%)
6 (10.2%) 0 (0%) 85(2.5%)
0 (0%) 1 (1.2%) 14 (0.4%)
46 (78.0%) 68 (81.9%) 2866 (83.9%) 0.54
6 (10.2%) 9 (10.8%) 439 (12.9%)
1 (1.7%) 2 (2.4%) 27 (0.8%)
6 (10.2%) 4 (4.8%) 84 (2.5%)
5 (8.5%) 15 (18.1%) 523 (15.3%) 0.26
33 (55.9%) 52 (62.7%) 2057 (60.2%)
18 (30.5%) 13 (15.7%) 680 (19.9%)
3 (5.1%) 3 (3.6%) 156 (4.6%)
17 (28.8%) 32 (38.6%) 1478 (43.3%) 0.19
28 (47.5%) 38 (45.8%) 1522 (44.6%)
5 (8.5%) 5 (6.0%) 142 (4.2%)
9 (15.3%) 8 (9.6%) 274 (8.0%)
7 (11.7%) 8 (9.6%) 398 (11.7%) 0.95
52 (88.1%) 74 (89.2%) 2979 (87.2%)
0 (0%) 1 (1.2%) 39 (1.1%)
45 (76.3%) 60 (72.3%) 2304 (67.5%) 0.39
1 (1.7%) 1 (1.2%) 97 (2.8%)
5 (8.5%) 4 (4.8%) 329 (9.6%)
8 (13.6%) 18 (21.7%) 686 (20.1%)
Table 3
Treatment choice by cognitive impairment level.
Cognition category











Surgery (+/− adjuvant therapy 2494 (84.9%) 248 (73.8%) 36 (61.0%) 33 (39.8%) <0.001
PET 365 (12.4%) 75 (22.3%) 21 (35.6%) 43 (51.8%)
No treatment/unknown 79 (2.7%) 13 (3.9%) 2 (3.4%) 7 (8.4%)









Surgery (+/− adjuvant 2139 (83.5%) 208 (71.2%) 30 (57.7%) 25 (33.8%) <0.001
PET 362 (14.1%) 75 (25.7%) 20 (38.5%) 43 (58.1%)
No treatment/ unknown 60 (2.3%) 9 (3.1%) 2 (3.8%) 6 (8.1%)
Adjuvant therapy Normal function Mild impairment Moderate impairment Severe impairment P value
Chemotherapy in women with high recurrence risk cancera 342/1346 (25.4%) 28/139 (20.0%) 4/18 (22.2%) 2/17 (11.8%) 0.32
Radiotherapy in women following BCS or high risk histology post mastectomyb 727/1161 (62.6%) 66/110 (60.0%) 9/15 (60%) 4/13 (30.8%) 0.12
Trastuzumab in women with HER-2 positive diseasec 126/289 (43.6%) 10/34 (29.4%) 1/4 (25.0%) 2/5 (40.0%) 0.39
a Among participants forwhomchemotherapy should be considered on the basis of having any of the following: (i) HER2+; ii) ER-; iii) ER+andhistological grade 3; iv) presence of one
or more positive lymph nodes or v) oncotype DX recurrence score of 30 or above.
b Among participants for whom radiotherapy should be considered on the basis of having any of the following aftermastectomy: i) tumour of > 5 cmor T4, ii) presence of four ormore
positive lymph nodes, iii) tumour resection margins positive, iv) histological grade 3 AND any nodal disease, v) nodal disease (1–3 nodes) if other risk factors such as adverse tumour bi-
ology (triple negative phenotype or HER-2 positive), or all women following breast conserving surgery.
c Among participants for whom Trastuzumab should be considered on the basis of a HER-2+ tumour greater than 0.5 cm.
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with an increasing rate of PET in the 2979 women with ER+ cancers.
Use of adjuvant chemotherapy following surgery was more similar be-
tween the groups. Among the 1520 women with high recurrence risk
cancer, chemotherapywas given to 342/1346 (25.4%)womenwith nor-
mal cognition compared to 28/139 (20.0%) withmild impairment, 4/18
(22.2%) with moderate impairment, and 2/17 (11.8%) with severe im-
pairment (p = 0.321). The use of radiotherapy and trastuzumab were
slightly higher among patients with normal cognitive function, though
not significantly so. Similarly, analysis of the use of trastuzumab was
limited by small numbers of patients with cognitive impairment and
HER2 positive disease. Use of radiotherapy (if indicated by breast con-
servation surgery or high risk histology after mastectomy) also ap-
peared higher in the normal cognition group, although numbers did
not reach statistical significance (P < 0.12, Table 3). There were 727/
1161 (62.6%) with normal cognition having radiotherapy compared to
4/13 (30.8%) in those with severe CI.
3.4. Surgical Treatment
Breast cancer surgery was significantly higher in women with
normal cognition compared to cognitively impaired patients; 84.9% of
women with normal cognition underwent surgery compared to
women with mild (73.8%), moderate (61.0%), and severe (39.8%)Table 4
Breakdown of surgical treatment type for all patients undergoing surgery.
Cognition category
Type of surgery Normal function Mild im
Breast conserving treatment
Wide local excision 1432 (57.4%) 132 (53
Therapeutic mammoplasty 46 (1.8%) 3 (1.2%
Mastectomy
Mastectomy 911 (36.5%) 110 (44
Mastectomy & reconstruction 34 (1.4%) 1 (0.4%
Other 19 (0.8%) 0 (0%)
Missing 52 (2.1%) 2 (0.8%
Totals 2494 248
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impairment (p= 0.001). A total of 2735 surgeries could be categorised
according to cognition status with 56 cases missing data, which could
not be analysed. Of these, rates of wide local excision and mastectomy
were comparable across all groups. There was a trend for women with
cognitive impairment to undergo mastectomy compared to breast
conserving treatment, but this difference did not reach statistical signif-
icance (P< 0.19, Table 4). For women with normal function, the rate of
wide local excision (57.4%) was higher than those undergoing mastec-
tomy (36.5%), whereas for women with severe impairment, rates
were nearly equal (16/33, 48.5%). This may be accounted for by the
slightly larger primary tumour size seen in cognitively impaired
participants.3.5. Adverse Events and Systemic Complications
Data on adverse events relating to surgery and other treatments
were recorded during study follow-up according to standard Common
Terminology Criteria for Adverse Events (CTCAE) [38]. There were
seven systemic complications in patients with CI compared to 50 in
women with normal cognition (Supplemental Table 1). There was no
clear association between cognitive impairment and systemic complica-
tions following surgery, as numbers were too small for meaningful
analysis.pairment Moderate impairment Severe impairment
.2%) 18 (50.0%) 16 (48.5%)
) 1 (2.8%) 1 (3.0%)
.4%) 13 (36.1%) 15 (45.4%)
) 2 (5.6%) 0 (0%)
1 (2.8%) 0 (0%)
) 1 (2.8%) 1 (3.3%)
36 33
Table 5






Unadjusted 2.10 (1.77, 2.50) <0.001
Matched for age, treatment and NPI 1.39 (1.09, 1.78) 0.01
Matched for age, treatment, NPI and functionality 1.23 (0.94, 1.62) 0.13
Breast cancer specific survival
Unadjusted 1.39 (1.00, 1.93) 0.05
Matched for age, treatment and NPI 0.96 (0.61, 1.50) 0.86
Matched for age, treatment, NPI and functionality 0.93 (0.58, 1.49) 0.76
Progression free survival
Unadjusted 1.08 (0.74, 1.60) 0.68
Matched for age, treatment and NPI 1.43 (0.89, 2.28) 0.14
Matched for age, treatment, NPI and functionality 0.91 (0.52, 1.60) 0.74
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Patients with cognitive impairment had reduced overall survival
compared to those without impairment (hazard ratio: 2.10, 95% CI
1.77 to 2.5, p < 0.001), but the effect was greatly reduced (although
not removed) when comparing patients matched for other characteris-
tics (Fig. 2; Table 5). The effect sizes were similar for both models:
matching for age, NPI, ER and treatment gave a hazard ratio (HR) of
1.39 (95% CI 1.09 to 1.78, p = 0.01) whilst adding functionality, nutri-
tion and co-morbidity gave a HR of 1.23 (95% CI 0.94 to 1.62, p =
0.13). By contrast, both breast cancer specific survival and
progression-free survival were similar with no significant difference in
hazard both with and without propensity matching despite the differ-
ences in treatment allocation.
4. Discussion
This analysis demonstrates the variation between the treatments
that older women with CI receive compared to women with normal
cognitive function. The use of PET is increased in womenwith cognitive
impairment, particularly those with severe impairment. Similar figuresFig. 2. Kaplan-Meier survival curves (overall, breast cancer specific and progression free surv
impairment.
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were found by Hooper and colleagues [39], with PET offered to 62% of
patients with co-morbidities (inclusive of dementia). This practice is
in keeping with UK NICE guidelines which state that PET can be anival) and comparisons between propensity matched patients with and without cognitive
C. Martin, A. Shrestha, J. Morgan et al. Journal of Geriatric Oncology xxx (xxxx) xxxappropriate option forwomenwith ER+ tumours, short life expectancy
or those considered too frail to withstand surgery [40].
In the sub-analysis of ER+ cases, the rate of PET use in patients with
normal cognitionwas significantly lower than in womenwith cognitive
impairment. These findings are reflected in other studies which present
the view that in some cases, non-surgicalmanagementmay bemore ap-
propriate for women with ER+ cancers [41,42]. In this study, rates of
PET in patients with dementia were higher than reported in the recent
UK national audit (NABCOP) rate of 24% [20]. However, the NABCOP
audit reported all women over 70 and did not sub-analyse for a cohort
with cognitive impairment.
The study observed a decrease in surgical management in women
with cognitive impairment (Supplemental Material 2). Reasons for
lower rates of breast conserving surgery in the cognitively impaired
groups may include clinicians offering PET due to a perceived risk of
co-morbidities and age, patient and caregiver preferences for what is
perceived as a lower risk/lower morbidity option in women with
lower life expectancy, and awishon thepart of patients' caregiver to op-
timise quality of life. Another factor may be clinician preference [26]
where cognitive impairment has been shown to be a significant clinician
driver for non-surgical treatment [11].
Women with cognitive impairment were slightly more likely to un-
dergo mastectomy compared to women with normal cognition, al-
though this difference did not reach statistical significance. This may
reflect a desire to avoid post-operative radiotherapy [43] ormay be a re-
sult of larger tumour sizes seen in women with cognitive impairment.
Other drivers for mastectomy may include patient or caregiver prefer-
ence, the desire to optimise patient outcomes; local disease control
and a reduced risk of recurrence are often perceived as more likely
with mastectomy, despite evidence to the contrary [44]. There may be
a perception that a patient with CI may be less concerned about body
image. In contrast it could also be argued that wide excision is less
major surgery with a lower risk of morbidity for a group of patients
who are generally in poorer health.
In this study, cognitive impairment was associated with a decreased
rate of overall survival, which includes death from all causes, including
breast cancer. This is to be expected as our study participants with cog-
nitive impairment were older, had poorer functional status and higher
rates of co-morbidities. When propensity matched analysis was per-
formed, the difference in overall survival is reduced but remains signif-
icant. When breast cancer specific survival was examined, there was
minimal difference in outcomes between patients with and without
cognitive impairment and this disappeared completely when matching
was performed. This suggests that non-breast cancer causes of death are
relatively more important in patients with dementia, and the selective
use of PET in the cohort of older women with ER+ breast cancer does
not increase breast cancer specific mortality.
Systemic complications reported in this study were low, which sug-
gests that treatment tolerance in patients with cognitive impairments is
acceptable, although another explanation may be that some adverse
events are underreported in cognitively impaired groups. There were
no deaths attributed to surgery in the study [25] although there were
five deaths within 90 days of surgery (which suggests these women
were over-treated). In general those individuals at the greatest risk of
surgical morbidity received PET, keeping surgical mortality to a mini-
mum. Follow-up at 52months showed no difference in rates of progres-
sion free survival, and rates of local control were similar between
groups.
4.1. Study Limitations
Bridging the Age Gap is one of the largest prospective studies of
treatment and outcomes in patients over 70, and has uniquely collected
detailed data about cognitive status by permitting proxy consent of pa-
tients with cognitive impairment [26,45]. In addition, the study col-
lected detailed baseline health and fitness status allowing us to tease7
out the contribution of impairment from other co-morbidities, frailty
and older age, which often confound these analyses. There are some
limitations to the categorisation of proxy consented patients, as this
group were not expected to complete a MMSE form. Cognitive severity
was not formally assessed for women who self-consented to the study
and had a diagnosis of dementia indicated on the Charlson form, unless
a MMSE score was available. A review of medications was performed
where MMSE was unavailable for these women. Cognitive impairment
was only recorded at baseline, whichmay also be viewed as a limitation
of the study.
The first propensity matching technique was relatively simple and
only matched for age, tumour stage and biology, and treatment type.
In particular, the matching did not include other co-morbidities which
may have been a source of bias when attempting to show association
of cognitive impairment with survival. By contrast, the second match
(which included co-morbidity score and measures of functionality)
may have caused overmatching, wherein the impact of dementia on
outcome is diluted by including patients in the matched group that
were similar in terms of underlying cognition [46].
A second limitation is missing data. This was due to some patients
choosing not to complete optional questionnaires (ADL,MMSE) and un-
available data on treatment, adverse events and HER2 status. The data
do however have advantages over registry data where dementia sever-
ity is not categorised andmay be less fully or accurately recorded than in
this prospective observational cohort study. Finally, follow-up of this co-
hort is only 52months and longer term follow-upwill be needed to val-
idate the survival outcomes, especially for women with ER+ cancers,
where events occur over several decades.
4.2. Clinical Implications
The variation in treatment offered to older women is reflected in the
lack of best practice evidence-based guidelines that take into account
the heterogeneity of frailty and fitness levels in older age groups.
Older women continue to be poorly represented in randomised trials
[47], meaning that there is little guidance on whether surgery or PET
ismore beneficial forwomenwithmulti-morbidity.Where previous tri-
als have attempted to investigate this, the recruitment of older partici-
pants has been challenging [48]. As a result, there are a lack of data on
how older patients tolerate treatments, and there are no models or
guidelines to guide clinicians on the benefit of systemic therapies in pa-
tients over 80 years of age. There are also differences in opinion from cli-
nicians on how women within this age group should be treated [21].
5. Conclusion
This analysis confirms that the severity of cognitive impairment is a
significant predictor of PET for older women with breast cancer, and
cognition appears to play a significant part in deciding how to treat
older womenwith breast cancer. The presence of cognitive impairment
is linked to higher rates of overall mortality but has limited impact on
breast cancer related death, suggesting that breast cancer is being ade-
quately (not under-)treated in this group, despite the reduced treat-
ments delivered. The high rate of non-breast cancer causes of death at
one year after diagnosis may suggest that some of these women may
have been over-treated. Careful consideration must be given to a more
tailored approach in these women.
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